Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Cancer Prev Res (Phila). 2013 May 16;6(7):646–655. doi: 10.1158/1940-6207.CAPR-13-0083

Figure 5. Celecoxib protects against an increase in urinary PGE-M in a subset of zileuton treated subjects.

Figure 5

Proportion of cases with a post-treatment increase in urinary PGE-M levels was significantly smaller in those treated with zileuton and celecoxib combined therapy compared to those treated with zileuton alone [6% (1/16) vs. 37% (19/52); P=0.03, Fisher’s exact test].